In the last 40 years, mechanical circulatory support devices have become an effective option for the treatment of endstage heart failure in adults. Few possibilities, however, are available for pediatric cardiopulmonary support. Ension Inc. (Pittsburgh, PA) is developing a pediatric cardiopulmonary assist system (pCAS) intended to address the limitations of existing devices used for this patient population. The pCAS device is an integrated unit containing an oxygenator and pump within a single casing, significantly reducing the size and blood-contacting surface area in comparison to current devices. Prototype pCAS devices produce appropriate flows and pressures while minimizing priming volume and preparation time. The pCAS was tested on a mock circulation designed to approximate the hemodynamic parameters of a small infant using a 10-Fr. extracorporeal membrane oxygenation inflow cannula and an 8-Fr. extracorporeal membrane oxygenation outflow cannula. Revision 4 of the device provided a flow rate of 0.42 L/min at 6,500 RPM. Revision 5, featuring improved impeller and diffuser designs, provided a flow rate of 0.57 L/min at 5,000 RPM. The performance tests indicate that for this cannulae combination, the pCAS pump is capable of delivering sufficient flows for patients <5 kg.
The early 1960s witnessed the first attempts to develop ventricular assist devices (VADs). Since that time both technology and medical management of VAD patients have progressed significantly. Mechanical assist devices have now been shown to be more effective than optimum medical management and are being used with more regularity every year. 1 Despite these advances, there have been relatively few devices made available in the past 40 years for the treatment of children in need of cardiac or cardiopulmonary support.
Today there are nearly 40,000 children born with congenital heart disease every year in the United States. Of these 40,000 children, 25% will require invasive treatment to correct or palliate these defects, creating the need to provide cardiopulmonary bypass during surgery, as well as circulatory support in the pre-or postoperative periods. 2 The first attempts at pediatric mechanical circulatory support were undertaken in 1963 using a roller pump and small disk oxygenator to provide postoperative support to a 6-year-old female. 3 Since that initial groundbreaking treatment there have been ongoing attempts to provide mechanical pediatric support.
Currently, the most commonly used treatment option is extracorporeal membrane oxygenation (ECMO). ECMO systems include both pump and oxygenator and are most commonly used to provide cardiopulmonary support, although they are also used in situations where only cardiac support is needed. Although ECMO has a success rate of approximately 75% depending on the indication, the technique is plagued by complications including thrombosis and bleeding (Tamblyn J, personal communication, 2003). 4 -9 ECMO requires a great deal of circuit assembly which prolongs set up time in an emergency situation and requires extensive training for its operators. ECMO circuits also require a large priming volume which may create challenges in relation to the small blood volumes of pediatric patients and increases the blood contact with foreign materials which can stimulate an inflammatory response.
In an effort to alleviate the morbidities associated with the existing ECMO systems and extend the use of mechanical support to a wider range of pediatric patients, the National Heart, Lung, and Blood Institute issued five research contracts to develop five new pediatric cardiac assist systems. 2 Four of these systems are either pulsatile or continuous flow VADs. Ension Inc. (Pittsburgh, PA), as one of the contractors, has developed an integrated pump oxygenator which is capable of providing both cardiac and pulmonary support to neonates and small children. This device, the pediatric cardiopulmonary assist system (pCAS), is intended for short-term stabilization of preoperative neonatal and infant patients or patients requiring postoperative support. The integrated pCAS design results in reduced priming volume and blood-contacting surface area. A key feature of the pCAS is the Ension biologic coating intended to minimize the need for systemic heparin and to prevent plasma breakthrough. It is anticipated that once the initial version is finalized and proven adequate, a second, larger device will be developed with the capability of supporting children up to 25 kg.
Methods
The pCAS system employs a design which incorporates both oxygenator and pump into a single housing, providing a significant reduction in blood-contact surface area and priming volume as compared with currently employed systems (Figure 1 ). This reduction in tubing and equipment is expected to reduce inflammatory response and lower the necessary anticoagulation medication required. The minimal space required by the system creates the possibility of a greater interaction between the patient and parent during treatment and easier patient transport. Research has shown that parent-infant interaction in the neonatal period is essential in the bonding process and has a profound affect on the patient's later social abilities. 10 -12 It is anticipated that this new device will allow a newborn on cardiopulmonary support to be touched and held by the parents and the nurse.
The pCAS system must be able to provide an adequate flow to restore the normal hemodynamic parameters while reducing volume, contact surface area, and hemolysis at the same time. The following design criterion has been laid down by the developers and is thought to be sufficient for the patient population described. The device must be capable of delivering flows of 1 L/min for children up to the weight of 10 kg, provide oxygen transfer ranging from 40 to 150 ml/min depending on the size of the patient (newborns require a calculated 22 ml/min and children a calculated 121 ml/min), and achieve a carbon dioxide clearance of 32-120 ml/min (newborns require a removal of 17 ml/min and children a calculated 97 ml/min).
The entire unit consists of an integrated oxygenation fiber bundle and electrically driven pump. An inlet cannulae may be placed either into the right atrium if the chest is open or inserted into the jugular vein and advanced to the right atrium if a peripheral insertion is deemed appropriate by the surgeon. Similarly, the outlet cannulae may be placed directly into the aorta if the chest is opened or into a peripheral artery (i.e., the carotid). Once attached and primed, the pump may be set to provide either pulsatile or continuous flow. This investigation is limited to the in vitro pumping performance testing of the pCAS when operated in continuous flow mode with inflow and outflow cannulae selection appropriate for a neonate.
In vitro pumping performance of Revision 4 of the pCAS was evaluated using a mock circulation loop that approximates the key anatomic features and hemodynamics of a small infant ( Table 1) . The mock loop system employs the use of two pneumatically driven, 10-ml VADs which simulate the native right and left ventricles. Atria are simulated through the use of 1 in diameter bladder bags, and compliance is created through the use of 1 ⁄2 in Penrose drain tubing in the pulmonary artery and descending aorta components of the loop. The remainder of the loop is a sequence of tubing which simulate the pulmonary and systemic circuits and incorporate adjustable pinch clamps to establish the needed vascular resistance in each region (Figure 2) . Consistent with anticipated clinical use under conditions for neonatal support, the right atrium was cannulated with a 10 Fr. ECMO inflow cannula (Medtronic Bio-Medicus, Mineapolis, MN); the aorta was cannulated with an 8 Fr. ECMO arterial cannula for the pump outflow. The cannulae were connected to the pCAS inlet and outlet using 60 cm of 1 ⁄4 in I.D. bypass tubing. The total tip-to-tip priming volume of the cannulae, tubing, and pump/oxygenator was 80 ml.
Right atrial pressure (RAP), left atrial pressure (LAP), pCAS inlet and outlet pressures, and aortic pressure (AoP) were measured with high-fidelity pressure catheters (Millar Instruments, Houston, TX). The aortic flow, brachiocephalic flow, pulmonary artery flow, and the pCAS outflow were measured with ultrasonic, transit-time flow probes (Transonic Systems, Inc, Ithica, NY). All transducers were precalibrated against known standards to ensure measurement accuracy. Hemodynamic data was signal conditioned and analog-to-digitally converted at a sampling rate of 400 Hz and stored for digital data analysis using a Good Laboratory Practices compliant data acquisition (DAQ) system. 13 The test fluid was a 40% glycerin/water, blood-analog fluid ( ϭ 3.7 cP at 22°C @ 250 sec Ϫ1 comparable to a hematocrit of 45%). Each test run was initiated by establishing baseline hemodynamic conditions (heart rate ϭ 120 bpm, cardiac output ϭ 800 ml/min, mean AoP ϭ 75 mm Hg, mean RAP ϭ 4 -8 mm Hg, and mean LAP ϭ 8 -12 mm Hg). These hemodynamic values were selected based on intraoperative data collected at Primary Children's Hospital (Salt Lake City, UT) and Kosair Children's Hospital (Louisville, KY) and ongoing animal experiments conducted in appropriately sized piglets. 14, 15 Pumpstop reverse flow was determined by unclamping the cannulae with the pump at 0 RPM. The RPM was initially increased until the zero-flow RPM, the setting at which no net flow passes through the pump, was identified. The RPM was then in- creased in 500 RPM increments with the systemic vascular resistance element of the mock circulation adjusted to maintain a mean AoP of 75 mm Hg for each RPM setting with the resulting pump outflow rate noted. The RPM increments were continued until the controller reached the maximum operating RPM. The test sequence was completed three times and the data at each test point averaged over the three runs.
The Revision 5 version of the pCAS resulted from a redesign of the pump impeller and diffuser that were anticipated to result in greater pCAS flow rates at lower RPM compared with the Revision 4 device. The controller for the new pump was connected and the Revision 5 pump primed in the same manner as the previous version. The tip-to-tip priming volume of the fifth revision was also 80 ml of the 40% glycerin solution. The same test protocol used for Revision 4 was used for Revision 5 using the same mock loop and DAQ system.
Results
At the maximum RPM of approximately 6,500, an average flow rate of 0.42 L/min was delivered by the Revision 4 pCAS (Figure 3) . As shown in Figure 3 , as the RPMs are increased, the change in pressure increases across the pump according to a second-order equation, with a maximum difference of nearly 300 mm Hg. Upon initial unclamping of the device a reverse flow equal to Ϫ0.12 L/min was observed. The zero-flow RPM setting was approximately 2,700. The change in pressure across the cannulae was also measured. Inflow cannula pressure drop was defined as RAP-inlet pressure and resulted in a maximum value of 47 mm Hg at an inlet pressure of Ϫ41 mm Hg. Outflow cannula drop was defined as outflow pressure-AoP and was found to be 213 mm Hg.
The same inflow and outflow cannulas, mock loop, and protocol were followed for the testing of the Revision 5 of the pCAS pump. As was anticipated, the larger, more efficient impeller produced higher flow rates at lower RPMs (Figures 4  and 5) . Despite the improvement in impeller efficiency, however, there still existed a large pressure difference between the pump inlet and outlet, which was increased at the higher flow rates achieved with the newly revised pump (Figure 4) . The reverse flow through the pump when the RPM was zero was Ϫ0.15 L/min. The zero-flow speed of the revised pump was lowered to an average of 1,870 RPM. At the maximum RPM setting of 5,000, the flow rate was measured at 0.57 L/min, which is double that of the Revision 4 pCAS at the same RPM (Figure 5) . The maximum pressure drop across the inflow cannula was seen to increase to 89 mm Hg at an inlet pressure of Ϫ87 mm Hg. The maximum pressure drop across the outflow cannula was found to be 279 mm Hg.
Discussion
The developing series of pCAS devices has demonstrated adequate pumping ability for neonates up to 5 kg. Modifications in the Revision 5 pCAS improved the pump performance at the same RPM compared with the Revision 4 pCAS. A major concern of pump operation for these tests is the lower inlet pressure at higher flow rates (Figures 3 and 4) . This lower pressure is mostly due to the high resistance of the small cannulae used in this particular testing and the viscosity of the test fluid used. In previously published articles it has been shown that an extremely negative inflow pressure, one exceeding Ϫ20 mm Hg, may result in high levels of hemolysis. 16 Extreme or rapid changes in pressure can also be traumatic to blood cells and are therefore concerning as the blood moves from a very low inflow pressure to a very high outflow pressure. However, the mock circulation was created to represent a challenging clinical scenario, creating higher levels of resistance with the smallest cannula than may be seen during common use. In the animal testing of the Revision 4 pCAS, larger cannulae which would be more commonly used clinically in larger patients resulted in both higher flow rates (Ͼ1 L/min), and much smaller pressure gradients and inlet pressures than seen in the mock circulation experiments. This result would also be expected in a situation where the hematocrit was lower, such as neonates and infants with noncyanotic heart disease. It is expected that during animal studies of the new revisions of the pCAS, similar performance improvements will be seen as well as definition of maximum acceptable flow rates and pump speeds permissible before creating unacceptable hemolysis as indicated by plasma-free hemoglobin.
The new pCAS utilizes a small, versatile pump which is highly advantageous in a pediatric assist system. The ability to operate in both a continuous and pulsatile mode provides the ability to stabilize critically ill patients while still maintaining a reasonable level of systemic pulsatile flow that has been considered as a possible benefit. 17 It is the expectation that this device will offer access to life-saving procedures to a wider range of pediatric patients or grant them a time period sufficient to recover diminished myocardial and pulmonary function while reducing the complications experienced with ECMO. The next revisions of the pCAS are already in early in vitro testing with initial chronic tests scheduled for the autumn of 2008. A preclinical readiness testing program is being planned for 2009 with initial clinical trials anticipated in 2012.
Conclusion
A small and portable cardiopulmonary assist device like the pCAS could provide a number of advantages in the treatment of pediatric patients. This device not only allows for stabilization of a failing heart or lungs, but may also provide adequate support for use during or after surgical procedures in which a pediatric patient needs to be placed on cardiopulmonary bypass. The Revision 4 and Revision 5 pCAS pump/oxygenator devices were tested in vitro under conditions comparable to a neonatal patient. Both devices delivered adequate flow rates for neonates up to 5 kg. The improved design of the Revision 5 pCAS was able to produce greater flow at a lower RPM which may reduce the hemolysis potential of the device in vivo. Final revisions of the pCAS are in progress as plans for preclinical testing are being considered.
